St. Jude Medical Inc. is touting the benefits of fractional flow reserve as a guide to stenting in patients with stable coronary artery disease following last week’s release of the full results of its FAME II trial. But some clinicians are questioning the extent to which the study’s findings should impact clinical practice.
The study is potentially significant not only for the use of fractional flow reserve (FFR) devices, but also for the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?